SOUTH SAN FRANCISCO, Calif.,
Sept. 19, 2019 /PRNewswire/
-- Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today
announced the appointment of Ted W.
Love, M.D., to its Board of Directors. Dr. Love is a
recognized industry leader with more than 25 years of experience in
the discovery and development of high impact medicines.
Dr. Love currently serves as president and chief executive
officer of Global Blood Therapeutics. He previously held executive
positions at a number of large biopharmaceutical companies
including Onyx Pharmaceuticals, Nuvelo, Inc. and Theravance, Inc.
Earlier in his career, Dr. Love held a number of senior management
positions at Genentech, where he oversaw the development strategy
and execution that led to the approvals of six innovative
medicines.
"Ted is an accomplished leader with deep scientific knowledge
and an outstanding track record driving growth, advancing medical
innovation and creating shareholder value," said Hollings C. Renton, Portola's Chairman of the Board. "We are
pleased to welcome him to our Board during this important stage of
the Company's evolution. His strategic guidance and insights will
be invaluable as we continue our transition into a global,
commercial organization."
"I am honored to join the Portola Board at such a significant point in
the Company's history and I look forward to partnering with the
Board and leadership team to help advance the Company's growth
objectives, deliver life-saving medicines to patients around the
world and create sustained value for shareholders," said Dr.
Love.
Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in
internal medicine and a fellowship in cardiology at the
Massachusetts General Hospital. He currently serves on the board of
directors of Amicus Therapeutics, Inc. and the Biotechnology
Innovation Organization, and has served as a consultant in medicine
in the Department of Cardiology at the Massachusetts General
Hospital.
About Portola Pharmaceuticals, Inc.
Portola
Pharmaceuticals is a global, commercial-stage biopharmaceutical
company focused on the discovery, development and commercialization
of novel therapeutics that could significantly advance the fields
of thrombosis and other hematologic conditions. The Company's first
two commercialized products are Andexxa® [coagulation
factor Xa (recombinant), inactivated-zhzo], marketed in
Europe as Ondexxya®
(andexanet alfa), and Bevyxxa® (betrixaban). The company
also is advancing cerdulatinib, a SYK/JAK inhibitor being developed
for the treatment of hematologic cancers. Founded in 2003 in
South San Francisco, California,
Portola has operations in
the United States and
Europe.
Forward-Looking Statements
Statements contained in
this press release regarding matters that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to,
statements regarding Portola's
transition into a global, commercial organization, growth
objectives, the potential benefits of Portola's drugs and drug candidates and
potential effects on shareholder value. Risks that contribute to
the uncertain nature of the forward-looking statements include: the
risk that physicians, patients and payers may not see the benefits
of utilizing Andexxa for the indications for which it is approved;
our ability to continue to manufacture our products and to expand
approved manufacturing facilities; the possibility of unfavorable
results from additional clinical trials involving Andexxa; our
ability to grow our commercial operations in the EU and generate
product revenue within projected timelines and budget; the risk
that we may not obtain additional regulatory approvals necessary to
expand approved indications for Andexxa; our expectation that we
will incur losses for the foreseeable future and will need
additional funds to finance our operations; the accuracy of our
estimates regarding expenses and capital requirements; our ability
to successfully build a hospital-based sales force and commercial
infrastructure; our ability to obtain and maintain intellectual
property protection for our product candidates; our ability to
retain key scientific or management personnel and general market
conditions. These and other risks and uncertainties are
described more fully in our most recent filings with
the Securities and Exchange Commission, including our most
recent quarterly report on Form 10-Q. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. We undertake no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/portola-pharmaceuticals-appoints-ted-w-love-md-to-its-board-of-directors-300921341.html
SOURCE Portola Pharmaceuticals, Inc.®